Meilleure Health International Industry Group
Market Cap
HK$1.9b
Last Updated
2019/12/12 12:41 UTC
Data Sources
Company Financials +
Executive Summary
Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Meilleure Health International Industry Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2327's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.3%
2327
2.6%
HK Trade Distributors
2.2%
HK Market
1 Year Return
11.7%
2327
-4.7%
HK Trade Distributors
-0.8%
HK Market
Return vs Industry: 2327 exceeded the Hong Kong Trade Distributors industry which returned -4.7% over the past year.
Return vs Market: 2327 exceeded the Hong Kong Market which returned -0.8% over the past year.
Shareholder returns
| 2327 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | 2.6% | 2.2% |
| 30 Day | -12.2% | -22.5% | -0.6% |
| 90 Day | -24.6% | -21.8% | -0.9% |
| 1 Year | 11.7%11.7% | -1.5%-4.7% | 2.8%-0.8% |
| 3 Year | 12.1%10.3% | -14.3%-21.2% | 19.5%7.4% |
| 5 Year | 50.8%48.3% | -51.8%-59.7% | 20.7%0.5% |
Price Volatility Vs. Market
How volatile is Meilleure Health International Industry Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Valuation
Is Meilleure Health International Industry Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2327 (HK$0.43) is trading below our estimate of fair value (HK$3.23)
Significantly Below Fair Value: 2327 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2327 is poor value based on its PE Ratio (20.5x) compared to the Trade Distributors industry average (9.1x).
PE vs Market: 2327 is poor value based on its PE Ratio (20.5x) compared to the Hong Kong market (10.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2327's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2327 is overvalued based on its PB Ratio (1.6x) compared to the HK Trade Distributors industry average (0.6x).
Next Steps
Future Growth
How is Meilleure Health International Industry Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
9.7%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2327's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if 2327's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2327's revenue (9.7% per year) is forecast to grow slower than the Hong Kong market (10.3% per year).
High Growth Revenue: 2327's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2327's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Meilleure Health International Industry Group performed over the past 5 years?
42.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2327 has a large one-off gain of HK$61.6M impacting its June 30 2019 financial results.
Growing Profit Margin: 2327's current net profit margins (39.9%) are lower than last year (61.4%).
Past Earnings Growth Analysis
Earnings Trend: 2327's earnings have grown significantly by 42.1% per year over the past 5 years.
Accelerating Growth: 2327's earnings growth over the past year (1.9%) is below its 5-year average (42.1% per year).
Earnings vs Industry: 2327 earnings growth over the past year (1.9%) exceeded the Trade Distributors industry 1%.
Return on Equity
High ROE: 2327's Return on Equity (6.8%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Meilleure Health International Industry Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2327's short term assets (HK$999.2M) exceed its short term liabilities (HK$300.9M).
Long Term Liabilities: 2327's short term assets (HK$999.2M) exceed its long term liabilities (HK$355.4M).
Debt to Equity History and Analysis
Debt Level: 2327's debt to equity ratio (31.3%) is considered satisfactory.
Reducing Debt: 2327's debt to equity ratio has reduced from 101% to 31.3% over the past 5 years.
Debt Coverage: 2327's debt is well covered by operating cash flow (32.7%).
Interest Coverage: 2327's interest payments on its debt are well covered by EBIT (4.2x coverage).
Balance Sheet
Inventory Level: 2327 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 2327's debt is covered by short term assets (assets are 2.7x debt).
Next Steps
Dividend
What is Meilleure Health International Industry Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 2327's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2327's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2327's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2327's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 2327 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2327's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
What is the CEO of Meilleure Health International Industry Group's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Wen Chuan Zhou (36yo)
6.3yrs
Tenure
HK$540,000
Compensation
Ms. Wen Chuan Zhou has been the Chief Executive Officer and Executive Director of U-Home Group Holdings Limited since September 23, 2013. Ms. Zhou has been Vice Chairman of U-Home Group Holdings Limited. S ...
CEO Compensation Analysis
Compensation vs Market: Wen Chuan's total compensation ($USD69.12K) is below average for companies of similar size in the Hong Kong market ($USD296.65K).
Compensation vs Earnings: Wen Chuan's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
53yo
Average Age
Experienced Management: 2327's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
4.2yrs
Average Tenure
57yo
Average Age
Experienced Board: 2327's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 8,382,000 |
| Max Price | HK$0.51 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 8,772,000 |
| Max Price | HK$0.65 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 1,200,000 |
| Max Price | HK$0.66 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 6,600,000 |
| Max Price | HK$0.63 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 4,500,000 |
| Max Price | HK$0.74 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 3,000,000 |
| Max Price | HK$0.81 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen & Executive Director |
| Shares | 15,000,000 |
| Max Price | HK$0.91 |
| Entity | Individual |
| Role | Co-Chairman of the Board Co-Chairmen of the Board |
| Shares | 43,002,000 |
| Max Price | HK$0.91 |
| Entity | Company |
| Shares | 9,180,000 |
| Max Price | HK$1.48 |
| Entity | Company |
| Shares | 2,292,000 |
| Max Price | HK$1.43 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 90,000 |
| Max Price | HK$1.60 |
| Entity | Company |
| Shares | 3,390,000 |
| Max Price | HK$1.50 |
| Entity | Company |
| Shares | 1,248,000 |
| Max Price | HK$1.17 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.
Management Team
Man Chun Chu (59yo)
Human Resources Manager
- Tenure: 0yrs
Chun Xia Liu (57yo)
Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltd
- Tenure: 0yrs
Dong Mei Luo (50yo)
Executive Assistant to Chairman and COO of Kunming Jida Pharmaceutical Company Ltd
- Tenure: 0yrs
Chen Bang Hua (64yo)
President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limited
- Tenure: 0yrs
Pu Feng (47yo)
Chief of R&D Dept - Kunming Jida Pharmaceutical Company Ltd and Director of R&D Dept - Kunming Jida
- Tenure: 0yrs
Man Fai Shek (44yo)
Financial Controller
- Tenure: 0yrs
Xuzhou Zhou (63yo)
Co-Chairmen of the Board
- Tenure: 0.6yrs
- Compensation: HK$500.00k
Wen Chuan Zhou (36yo)
Vice Chairman & CEO
- Tenure: 6.3yrs
- Compensation: HK$540.00k
Shu Pai Li (43yo)
CFO & Company Secretary
- Tenure: 0.4yrs
Wentao Zeng (56yo)
Co-Chairmen & Executive Director
- Tenure: 0yrs
- Compensation: HK$120.00k
Board Members
Wilton Chau (58yo)
Independent Non-Executive Director
- Tenure: 6.3yrs
- Compensation: HK$120.00k
Chun Xia Liu (57yo)
Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltd
- Tenure: 0yrs
Chen Bang Hua (64yo)
President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limited
- Tenure: 0yrs
Zhenhua Mao (55yo)
Non-Executive Director
- Tenure: 4.2yrs
- Compensation: HK$120.00k
Xuzhou Zhou (63yo)
Co-Chairmen of the Board
- Tenure: 0.6yrs
- Compensation: HK$500.00k
Wen Chuan Zhou (36yo)
Vice Chairman & CEO
- Tenure: 6.3yrs
- Compensation: HK$540.00k
Guanjiang Gao (66yo)
Independent Non-Executive Director
- Tenure: 6.3yrs
- Compensation: HK$120.00k
Wentao Zeng (56yo)
Co-Chairmen & Executive Director
- Tenure: 0yrs
- Compensation: HK$120.00k
Peng Wu (36yo)
Independent Non-Executive Director
- Tenure: 0.6yrs
Company Information
Meilleure Health International Industry Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Meilleure Health International Industry Group Limited
- Ticker: 2327
- Exchange: SEHK
- Founded:
- Industry: Trading Companies and Distributors
- Sector: Capital Goods
- Market Cap: HK$1.858b
- Shares outstanding: 4.27b
- Website: https://www.meilleure.com.cn
Number of Employees
Location
- Meilleure Health International Industry Group Limited
- Tower 1
- Unit 2906
- Admiralty
- Hong Kong
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2327 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Oct 2003 |
Biography
Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China. It operates th ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/12 12:41 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.